Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine with or without homoharringtonine in relapsed/refractory acute myeloid leukemia
ChiCTR2000041402Phase 3Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, azacitidine and homoharringtonine in acute myeloid leukemia (AML) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall response rate. Started Jan 2021; status: completed.
02
Drugs
venetoclaxazacitidinehomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000041402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041402.